Page Menu

Central Nervous System Clinical Trials

Central nervous system clinical trials are an important part of cancer treatment for two main reasons. First, they allow certain patients with various types of brain and spinal cancer to be among the first to benefit from promising new treatment approaches. And second, as the best and most reliable way to determine the effectiveness of a new treatment, clinical trials provide the evidence physicians need to improve the care of all current and future cancer patients.

Moffitt Cancer Center is highly respected for the breakthroughs we’ve achieved through our research efforts and clinical trials, which have resulted in numerous advances in the prevention, diagnosis and treatment of cancer. Our work is recognized by the National Cancer Institute, which has awarded us the designation of Comprehensive Cancer Center. This honor is bestowed on only a select few institutions that have made a significant and proven impact on cancer care by translating laboratory discoveries into better outcomes and higher-quality lives for patients.

Currently, the researchers at Moffitt are working on developing promising new strategies for treating primary and metastatic brain and spinal tumors. Some of the treatments available in our central nervous system clinical trials include:

  • Vaccines
  • Immunotherapy
  • Biological therapies Intrathecal chemotherapy with standard drugs, biological agents and targeted molecular agents
  • Other novel chemotherapy agents and combinations that cross the natural barrier that protects the brain

We also offer clinical trials for metastatic brain and spinal tumors, including those associated with melanoma, lung cancer and breast cancer.

At Moffitt, we encourage our patients to consider enrolling in clinical trials as early as possible, and preferably at the time of diagnosis. A common misconception about clinical trials is that they are experimental. This is not the case. A participant in a clinical trial will receive either the standard of care, which is the best treatment currently available for the specific type of cancer, or a promising new treatment. Until a time when the standard of care for central nervous system tumors is curative, clinical trials will play a vital role in the treatment of brain and spinal cancers.

To learn more about the central nervous system clinical trials available at Moffitt Cancer Center, call call 1-813-745-6100 or 1-800-679-0775 (toll-free) or submit a clinical trials inquiry form online. We do not require referrals.

 

calledFromCancerPage=True - substr=
testProtocol=

Open Clinical Trials:

Showing of 50

CLINICAL TRIAL 18752

ACTION Trial- Adoptive Cellular Therapy following Dose-Intensified Temozolomide in Newly-diagnosed Pediatric High-grade Gliomas (Phase I)

Disease Site: Brain and Nervous System

View Trial Details

CLINICAL TRIAL 18778

A Phase 3, Randomized, Open-Label Study To Evaluate the Efficacy and Safety of Eflornithine with Lomustine Compared to Lomustine Alone in Patients with Anaplastic Astrocytoma That Progress/Recur After Irradiation and Adjuvant Temozolomide Chemotherapy

Disease Site: Brain and Nervous System

View Trial Details

CLINICAL TRIAL 19327

A Phase 2 Trial of Pembrolizumab Plus Bevacizumab in Patients with Metastatic Melanoma or Non-small Cell Lung Cancer with Untreated Brain Metastases

Disease Site: Non small cell lung cancer, Brain and Nervous System, Lung, Melanoma, skin

View Trial Details

CLINICAL TRIAL 19648

Phase IB Study of Avelumab with Radiotherapy in Patients with Leptomeningeal Disease

Disease Site: Brain and Nervous System

View Trial Details

CLINICAL TRIAL 19970

A Pilot Trial of Intratumorally-Administered Topotecan using Convection-Enhanced Delivery (CED) in Patients with Suspected Recurrent/Progressive WHO Grade III or IV (High Grade) Glioma Undergoing Stereotactic Biopsy (IND 117,240)

Disease Site: Brain and Nervous System

View Trial Details

CLINICAL TRIAL 20145

A Pilot Study of Intratumorally and Intraparenchymally Administered OS2966 using Convection-enhanced Delivery in Patients with Recurrent/Progressive High-grade Glioma Undergoing a Clinically-indicated Surgical Resection

Disease Site: Brain and Nervous System

View Trial Details

CLINICAL TRIAL 20347

A Phase 2 Basket Trial of Glutaminase Inhibitor (BeGIN) CB-839 HCl in Patients with NF1 Aberrations, NF1 Mutant Malignant Peripheral Nerve Sheath Tumors (MPNST), KEAP1/NRF2 and LKB1 Aberrant Tumors

Disease Site: Brain and Nervous System

View Trial Details

CLINICAL TRIAL 20637

Phase III Trial of Post-Surgical Single Fraction Stereotactic Radiosurgery (SRS) Compared with Fractionated SRS (FSRS) for Resected Metastatic Brain Disease

Disease Site: Brain and Nervous System

View Trial Details

CLINICAL TRIAL 20899

Phase I/II Study of Stereotactic Radiation and Abemaciclib in the Management of Hormone Receptor Positive HER2 Negative Breast Cancer Brain Metastases

Disease Site: Brain and Nervous System, Breast

View Trial Details

CLINICAL TRIAL 20956

A Two-Part, Phase 1a/B, Open-Label, Multicenter Trial Evaluating Pharmacokinetics, Safety and Efficacy Of PF-07284890 (ARRY-461) In Participants With BRAF V600-Mutant Solid Tumors With And Without Brain Involvement

Disease Site: Any Site, Brain and Nervous System, Larynx, Lip, Oral Cavity and Pharynx, Lung, Melanoma, skin, Other Skin

View Trial Details

CLINICAL TRIAL 20964

A Phase 2 Basket Study of Tucatinib in Combination with Trastuzumab in Subjects with Previously Treated, Locally-Advanced Unresectable or Metastatic Solid Tumors Driven by HER2 Alterations

Disease Site: Brain and Nervous System, Breast, Ill-Defined Sites, Lung, Other Digestive Organ, Urinary Bladder

View Trial Details

CLINICAL TRIAL 21070

A Multi-indication, Single-treatment Arm, Open-label Phase 2 Study of Regorafenib and Nivolumab in Combination in Patients with Recurrent or Metastatic Solid Tumors

Disease Site: Brain and Nervous System, Esophagus, Liver, Other Hematopoietic, Pancreas

View Trial Details

CLINICAL TRIAL 21084

A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of Enzastaurin Added to Temozolomide During and Following Radiation Therapy in Newly Diagnosed Glioblastoma Patients Who Possess the Novel Genomic Biomarker DGM1PI

Disease Site: Brain and Nervous System

View Trial Details

CLINICAL TRIAL 19731

Electronic Social Network Assessment Program (eSNAP) + Caregiver Navigator Intervention for Neuro-Oncology Couples

Disease Site: Brain and Nervous System

View Trial Details

CLINICAL TRIAL 50388

Targeting the Hemangiopericytoma NAB2-STAT6 Gene Fusion

Disease Site: Brain and Nervous System

View Trial Details

CLINICAL TRIAL 50399

Mechanisms of Functional Heterogeneity of Tumor Associated Macrophages in Glioblastoma

Disease Site: Brain and Nervous System

View Trial Details